IP Verse

Acerta Pharma competitive analysis

Latest publications and patents of Acerta Pharma New

Explore the latest publications and patents granted to Acerta Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 28, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Acerta Pharma

EP3954690
Apr 5, 2023Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)BenzamideGranted And Under Opposition
EP3179991
Oct 6, 2021Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 InhibitorGranted And Under Opposition
EP3317281
Apr 22, 2020Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1 -(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)BenzamideGranted And Under Opposition

Latest patents of Acerta Pharma opposed by its competitors

Explore Acerta Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3954690
Apr 5, 2023Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide1
EP3179991
Oct 6, 2021Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor1
EP3317281
Apr 22, 2020Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1 -(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide1

Latest PTAB cases involving Acerta Pharma

Discover the latest PTAB cases involving Acerta Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 4, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Acerta Pharma

IPR2023-00478Feb 3, 2023SANDOZACERTA PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Acerta Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
ACERTA PHARMA - 3 - 1Non-Active
KRAUS & LEDERER PARTGMBB67 - - - Highly Aggressive
SANDOZ1141519 - Highly Aggressive
STADA ARZNEIMITTEL10828 - - Highly Aggressive